Is canagliflozin effective in lowering the risk of all-cause mortality in adults with type 2 diabetes compared to the placebo? by Luu, Bao Tran
Philadelphia College of Osteopathic Medicine 
DigitalCommons@PCOM 
PCOM Physician Assistant Studies Student 
Scholarship Student Dissertations, Theses and Papers 
2021 
Is canagliflozin effective in lowering the risk of all-cause mortality 
in adults with type 2 diabetes compared to the placebo? 
Bao Tran Luu 
Philadelphia College of Osteopathic Medicine 
Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Luu, Bao Tran, "Is canagliflozin effective in lowering the risk of all-cause mortality in adults with type 2 
diabetes compared to the placebo?" (2021). PCOM Physician Assistant Studies Student Scholarship. 610. 
https://digitalcommons.pcom.edu/pa_systematic_reviews/610 
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student 
Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM 
Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For 










Is canagliflozin effective in lowering the risk of all-cause mortality in 
adults with type 2 diabetes compared to the placebo? 
 
Bao Tran Luu, PA-S  
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements For  
The Degree of Master of Science 
In 
Health Sciences – Physician Assistant 
 
 
Department of Physician Assistant Studies 













OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
“canagliflozin is effective in lowering the risk of all-cause mortality in adults with type 2 diabetes 
compared to the placebo?” 
 
STUDY DESIGN: A systematic review of three English language, primary, double-blind, 
randomized controlled trials published from 2013 to 2019. 
 
DATA SOURCES: All primary studies were published in peer reviewed journals and selected 
through PubMed and Cochrane databases comparing canagliflozin vs. placebo. 
 
OUTCOMES MEASURED: All-cause mortality, defined as death of patient within the study 
interval and expressed as number of death/ total participants over the study time interval. 
 
RESULTS: The search yielded a total of 20 articles. Three studies were ultimately included in the 
EBM review after exclusion of other irrelevant studies. Neal et al. showed no statistically 
significant reduction in all-cause mortality rate, 17.3 vs. 19.5 participants with an event per 1000 
patient-years between the intervention vs. placebo groups, respectively (HR 0.87; 95% CI 0.74 to 
1.01; P = 0.24). In the Perkovic study, all-cause mortality rate was also similar between both 
groups, 29.0 vs. 35.0 per 1000 patient-years (HR 0.83; 95% CI 0.68–1.02; P not given) for the 
intervention and placebo groups, respectively. Likewise, all-cause mortality rate was shown to be 
the same, 1.1 % in both the placebo and the treatment arms in Yale et al. study. 
 
CONCLUSIONS: The results of all three studies demonstrated that canagliflozin is not effective 
in lowering the risk of all-cause mortality in adults with type 2 diabetes compared to the matched 
placebo. Due to the potential heterogeneity among the included studies, the results of this analysis 
should be confirmed with new and larger trials in the future to better evaluate all-cause mortality 
over a longer follow-up period.  
 
KEY WORDS: Type 2 diabetes, canagliflozin, safety outcome
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INTRODUCTION 
Type 2 diabetes is a complex, chronic condition in which the body does not produce enough 
insulin and/or is unable to use insulin properly, leading to high levels of sugar in the bloodstream 
and causing a variety of serious complications, such as cardiovascular disease, vision loss, kidney 
disease and death. This disease, thus, has been a major concern for healthcare providers working 
in any field.1-3 Poorly controlled blood sugar and chronic hyperglycemia are detrimental to the 
body and associates with high mortality and morbidity due to the risk for developing 
cardiovascular disease is twofold in these patients.1 Moreover, type 2 diabetes can be caused by 
several factors, including overweight and obesity, sedentary lifestyle, insulin resistance, and 
genetics.1-3 Random plasma glucose tests, fasting plasma glucose tests, or HbA1c are often used 
to confirm the diagnosis. Patients may be asymptomatic or present with blurred vision, altered 
mental status, weakness, paresthesia, nausea, vomiting, anorexia, polydipsia, or polyuria. 
Per the CDC, 34.2 million Americans have diabetes.4 It is estimated that the prevalence of 
type 2 diabetes mellitus will continue to rise, specifically 25 to 33 percent of American adults 
could have diabetes by 2050, either diagnosed or undiagnosed, with the majority of them being 
45-64 years old.4 Moreover, the increasing management costs of type 2 diabetes and its 
complications has conferred a large economic burden on the U.S. healthcare system in recent 
years.4 The total estimated cost of diabetes in the United States was $327 billion in 2017, according 
to the American Diabetes Association.5 Of the spending spent on direct costs in 2017, hospital 
inpatient care and prescription medications to treat diabetes make up the largest components of the 
total spending cost.5 Furthermore, in 2016, there were 7.8 million hospital discharges were reported 
with diabetes as a listed diagnosis among US adults aged 18 years or older per the CDC.4  
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Optimal glycemic control is required to restrain the developing of serious complications in 
patients with type 2 diabetes, and this can be accomplished through carbohydrate counting, 
lifestyle modification and medications. Existing medications such as metformin, sulfonylureas 
(glyburide, glipizide), thiazolidinediones (rosiglitazone), alpha-glucosidase inhibitor (acarbose), 
incretin mimics: GLP1 receptor agonists (exenatide, liraglutide), DPP-4 inhibitors (sitagliptin, 
linagliptin), serum glucose co-transporter 2 inhibitor (dapagliflozin, canagliflozin), other: 
glucagon suppression and insulin, lower blood glucose either by enhancing insulin secretion or by 
improving insulin sensitivity. Most patients with type 2 diabetes will eventually maintain on a 
combination of different medications to achieve optimal glycemic control.1-3 However, deciding 
on an optimal treatment choice is a major challenge for healthcare providers, especially after 
inadequate treatment with metformin monotherapy, due to the constantly rising number of 
available antidiabetic medications. While the standard treatment options such as insulin, 
sulfonylureas, and DPP4 inhibitors all effectively lower blood glucose, these medications have not 
been associated with improvements in survival rate for type 2 diabetes patients.6 Conversely, the 
use of canagliflozin, a SGLT2 inhibitor, has been shown to have favorable effects in reducing the 
risk of serious cardiovascular complications and kidney disease,1,3 but whether or not 
canagliflozin, can produce similar effect on all-cause mortality is undetermined.  
SGLT2 inhibitors have been recommended by clinical guidelines as potential 
pharmacological approaches for second-line therapy following metformin failure or intolerance.6 
Canagliflozin, a SGLT2 inhibitor, decreases reabsorption of glucose at the proximal tubules in the 
kidneys, leading to greater urinary excretion, subsequently reducing in plasma glucose 
concentration, in individuals with hyperglycemia. Canagliflozin at a daily dose of 100 or 300 mg 
has received authorization in the U.S. for use in patients with type 2 diabetes, while its current 
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placement in the treatment algorithms is in second or third line of therapy.6 Also, there have been 
many favorable reports from multiple systematic reviews and meta-analyses about the effects of 
canagliflozin in reducing fasting blood sugar, lipid profile, blood pressure, HbA1C and body 
weight.7 Furthermore, empagliflozin, another SGLT2 inhibitor has shown benefits in the 
prevention of CV events and all-cause mortality in patients with CVDs from the EMPA-REG trial.8 
It is, therefore, suggested that canagliflozin has the potential to lower the risk of all-cause mortality 
in adults with type 2 diabetes. 
OBJECTIVE 
          The objective of this study is to determine whether or not “canagliflozin is effective in 
lowering the risk of all-cause mortality in adults with type 2 diabetes compared to the placebo?” 
METHODS 
The search for articles was performed using PubMed and Cochrane databases. Key words 
used to acquire literature included “type 2 diabetes”, “canagliflozin” and “safety outcome”. All the 
full-text studies published in English language and peer-reviewed journals from 2009 to 2019, 
were included in the review. Inclusion criteria was based on studies that were randomized, placebo-
controlled, their relevance to my clinical questions and that the outcomes of the studies mattered 
to patients (POEMs).   Exclusion criteria consisted of articles published before 2009, those that 
were not published in peer-reviewed journal and those that were not RCTs/prospective 
intervention studies, or secondary study design. Statistics reported included p-values, relative risk 
reduction (RRR), absolute risk reduction (ARR), and numbers needed to treat (NNT). Table 1 
expresses the specific demographics, inclusion, and exclusion criteria of each trial used in this 
review. 
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Three double blind, randomized control trials were selected to create this evidence-based 
medicine review. The populations of all selection of studies included patients >18yo with type 2 
diabetes. The intervention assessed in these studies was varying doses of canagliflozin in 
comparison to the placebo in type 2 diabetic patients. Outcome studied was the efficacy of 
canagliflozin in lowering the risk of all-cause mortality in adults with type 2 diabetes.  
OUTCOME MEASURED 
The primary outcome measured in all three studies was all-cause mortality of the patient. 
Mortality was defined as death of the patient within the study interval. All three studies expressed 
all-cause mortality result as number of death/ total participants over the time interval. 
RESULTS 
The search yielded a total of 20 articles. Three studies were ultimately included in the EBM 
review after exclusion of other irrelevant studies. All three randomized, placebo-controlled trials 
presented in this review involved data presented as an intention to treat analysis. The results 
regarding to the outcome measured were recorded as dichotomous data in all three studies. All 
participants in each study were randomly assigned to either the experimental group receiving 
canagliflozin, or the control group receiving a placebo. There was no clinically significant 
difference at baseline with regards to demographic characteristics in each trial. The ratio between 
the comparison and intervention group was 1:1 in all the studies. However, compared the 
population among each study, there are a differential proportion of enrolled cases with established 
CVD; for instance, 50% of patients enrolled in CREDENCE trial (Perkovic et al.), 66% of patient 
in CANVAS (Neal et al.), and 55% of patient in Yale et al. study had established CVD. While the 
CREDENCE trial had enrolled patients with chronic kidney disease and was required to be on 
ACE/ARB (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker) inhibitor 
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therapy, the other two studies did not have ACE/ARB inhibitor therapy as one of the inclusion 
criteria. It is also noted that while both Neal et al. and Perkovic et al. studies excluded only NYHA 
class IV patients, the Yale et al. study excluded both NYHA class III – IV patients. 
Table 1. Demographics & Characteristics of Included Studies 
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The Neal et al. study in 2017 compared canagliflozin to placebo in diabetic patients with 
high-risk cardiovascular disease. Participants received 100 mg of canagliflozin by mouth once a 
day for 12 weeks. Starting from week 13, there was an optional increase to 300 mg or matching 
placebo. All participants finished a 2-week, single-blind, placebo run-in period. The study 
comprised a total of 10,142 participants. A total of 9734 participants (96.0%) completed the trial. 
The mean follow-up was 188 weeks. The all-cause mortality rate was not significantly different 
between the groups, 17.3 vs. 19.5 participants per 1000 patient-years for the intervention vs 
placebo groups, respectively (HR 0.87; 95% CI 0.74 to 1.01; P = 0.24; Table 2). The statistical 
significance was defined as p<0.05. The absolute risk reduction (ARR) of this study was calculated 
to be 0.22% and the relative risk reduction (RRR) was 11%. The number needed to treat (NNT) 
was determined to be 455; hence the effect of the study was small (Table 3). 
In the Perkovic et al. study published in 2019, there were 4,401 patients with diabetes and 
albuminuria randomized to canagliflozin 100 mg or placebo. A total of 4361 participants (99.1%) 
completed the trial. Participants received a canagliflozin dose of 100 mg daily or placebo. All 
participants must receive a stable dose of an angiotensin-converting–enzyme inhibitor or 
angiotensin-receptor blocker for at least 4 weeks before randomization. At the trial conclusion a 
median follow-up was 2.6 years. The study was halted at 2.6 years due to early achieving 
prespecified efficacy criteria with canagliflozin. Secondary outcomes of this study including all-
cause mortality were planned for sequential hierarchical testing. Between groups, there was a non-
statistically significant difference for CV death outcome so subsequent outcomes including all-
cause mortality was not formally tested. At the termination of the trial, the all-cause mortality was 
reported as, 29.0 vs. 35.0 per 1000 patient-years (HR 0.83; 95% CI 0.68–1.02; P not given) for the 
intervention and placebo groups, respectively (Table 2). The author did not provide an estimation 
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of precision for all-cause mortality outcome. The ARR of this study was calculated to be 0.6% and 
the RRR was 17.1%. The calculated NNT was determined to be 167 which showed a small 
treatment effect. This difference is hence not clinically significance (Table 3). 
In Yale et al. study, all subjects either received canagliflozin 100 or 300 mg or placebo daily. 
This 52-week, randomized, double-blind, placebo-controlled, phase 3 study consisted of an 
antihyperglycemic agent adjustment period; a 2-week, single-blind, placebo run-in period; a 26-
week, double-blind, core treatment period; and a 26-week, double-blind, extension period. Of the 
272 randomized subjects, 269 received ≥1 dose of study drug and were included in the ITT analysis 
population. A total of 35 (12.9%) subjects discontinued before the week 26 visit, with fewer 
discontinuations in the canagliflozin 300 mg group compared with the canagliflozin 100 mg and 
placebo groups. A smaller proportion of subjects treated with canagliflozin 100 or 300 mg received 
glycemic rescue therapy before the week 26 visit compared with those treated with placebo (4.4, 
3.3 and 14.3%, respectively). Baseline demographic and disease characteristics were similar across 
the groups. All-cause mortality rate was 1.1% in both the placebo and the treatment arms (Table 
2). The calculated ARR and RRR of this study were both 0 (Table 3). Thus, there is no significant 
difference in the reduction of all-cause mortality risk observed with canagliflozin relative to the 
placebo. The author did not provide an estimation of precision for all-cause mortality outcome. In 
brief, the treatment effect of this study is small. The results of all three studies are summarized in 
Table 2. This data was reported as the number of deaths during the study interval. This information 
was presented in dichotomous form as those that died and those in the study that did not. Through 
this comparison the “control event rate” (CER) was determine as those receiving placebo who died 
and the “experimental event rate” (EER) as those administered canagliflozin who died. Using these 
numbers, the relative risk reduction and the absolute risk reduction were calculated. The numbers 
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need to treat was then computed to find out how many people would have to be treated with 
canagliflozin in order for one person to be positively affected.  
Table 2. Patient Mortality and p-value  
Study Canagliflozin Placebo P-value 
Neal et al.1 17.3 19.5 0.24 
Perkovic et al.2 29 35 Not given 
Yale et al.3 1 1 Not given 
 
Table 3. Efficacy of Treatment, Canagliflozin vs. Placebo 
Study CER EER RRR ARR NNT 
Neal et al.1 1.95% 1.73% 11% 0.22% 455 
Perkovic et al.2 3.5% 2.9% 17.1% 0.6% 167 
Yale et al.3 1.1% 1.1% 0% 0% undefined 
 
DISCUSSION 
This review aims to compare the results of the three RCT trials and provide healthcare 
workers with information regarding the efficacy of canagliflozin in reducing the risk of all-cause 
mortality outcomes in type 2 diabetes adults. Patients with diabetes are at high risk of developing 
serious complications despite having adequate glycemic control and especially after the failure or 
intolerance of metformin.  
The CANVAS (Neal et al.) trial showed that type 2 diabetics with CVD had a lower risk of 
death from CV causes but no significant difference in lowering the risk of all-cause mortality 
compared to the placebo. Similarly, the CREDENCE trial (Perkovic et al.) demonstrated the CV 
benefits of canagliflozin in diabetics with chronic kidney disease but no significant reduction in 
all-cause mortality rate. Similarly, Yale et al. study also did not show statistically significant result 
Luu: Canagliflozin and all-cause mortality 9 
 
in all-cause mortality outcome. The three studies included in this review were large randomized 
and strictly controlled trials with high rates of drug adherence and close monitoring of adverse 
events, so it is reasonable to draw a conclusion based on these studies that canagliflozin does not 
provide any benefit in lowering the risk of all-cause mortality in adults with type 2 diabetes. 
However, there were some differences in the follow-up periods among the trials, for example, 
CREDENCE was conducted for 2.62 years whereas the median follow-up for the CANVAS trial 
was 2.4 years and Yale et al. study was 26 weeks. It is possible that more prolonged drug 
administration can influence and produce different study outcomes than given for a smaller follow-
up duration.  
In addition, the studies chosen for this review did have certain limitations that need to be 
considered when interpreting the findings. First, none of the included studies were designed 
explicitly to assess all-cause mortality outcomes of SGLT2 inhibitors, even though all trials 
intended to evaluate the safety of SGLT2 inhibitors in patients with type 2 diabetes. Moreover, 
participants were not screened for subclinical atherosclerotic vascular disease in all three studies 
so those with asymptomatic CV disease may have not been included in the cohort; this can affect 
the generalizability of this study. In addition, the involved trials had a broad range of clinical 
characteristics among them, such as comorbid conditions, disease duration, and follow-up 
duration, which will undoubtedly lead to heterogeneity. Factors such as patient’s comorbid 
conditions, and lifestyle can impact the results of the study. Third, the Perkovic et al. study was 
terminated early at a planned interim analysis, which may have limited the power for some 
secondary outcomes of this study including the all-cause mortality and may impact the effect sizes. 
Lastly, there were some differences in the exclusion criteria among each study such as various 
classes of heart failure patients or chronic kidney disease, so it is not known whether the findings 
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can be generalized to such population. These limitations mentioned above may impair the power 
of this study. Future long-term study is, thus, warranted to enhance generalizability and validity of 
the use of canagliflozin in reducing all-cause mortality among adults with type 2 diabetes.  
CONCLUSION 
In summary, this EBM review evaluated the effects of canagliflozin in reducing the risk of 
all-cause mortality outcomes in patients with type 2 diabetes compared to matched placebo, and 
the results demonstrated that patients treated with canagliflozin experienced no significant 
difference in all-cause mortality lowering effects compared to the placebo. Due to the potential 
heterogeneity among the included studies, the results of this analysis should be confirmed with 
new and larger trials in the future to better evaluate all-cause mortality over a longer follow-up 
period. Discrepancies between study can be reduced by setting stricter inclusion and exclusion 
criteria. Having patients with similar co-morbid conditions and medical histories could 
strengthen the study although this might cause a decrease in the sample size. Furthermore, only 
canagliflozin has been investigated in this study and therefore we cannot generalize the same 
effect for all SGLT2i. Since the prevalence rates of type 2 diabetes continue to rise, the use of 
canagliflozin should continue to be studied. The benefits and risks of these medications must be 
considered carefully before prescribing by clinicians, keeping in mind the most important goal, 
that is, what is best for the patients. 
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